Revvity (RVTY) announced a strategic collaboration with Profluent. The result is simplified access for customers to a therapeutically relevant base editing toolkit. This new Pin-point configuration allows for increased precision and efficiency, with some combinations being precise to single nucleotide edits without bystander editing. Additionally, the Pin-point platform’s modular design has shown delivery of ultra-low amounts of deaminase while maintaining clinically-relevant levels of base editing and reducing off-target activity, which leads to enhanced safety. The result is a toolkit for therapeutic applications where control, safety, and reproducibility are paramount.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity’s Strategic Positioning and Valuation: A Buy Rating Despite Market Reactions
- Revvity management to meet with KeyBanc
- Revvity’s Strategic Growth and Valuation Position: A Buy Rating Amidst Challenges
- Revvity price target lowered to $110 from $120 at Stifel
- Revvity price target lowered to $115 from $120 at Raymond James